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numbers required to achieve signiﬁcance 
in a controlled trial, which increase with 
the mathematical factor: reciprocal of 
the data spread, squared1,15—applied to 
whichever variable is being assessed in 
a trial, for example, estimated GFR, or 
rate of loss of estimated GFR. In practice, 
this means that study patient numbers 
rise more than exponentially.1,15 Schena 
and colleagues’ study analysis12 assessed 
both of the latter variables in relation to 
urinary EGF/MCP-1. Doubtless, other, 
improved indices will be discovered, but 
urinary EGF/MCP-1 may be the best cur-
rent assay available as a prognostic tool to 
complement clinical characteristics in IgA 
nephropathy (Figure 1).
The value of intensive mathemati-
cal analysis of data in collaboration with 
dedicated clinical statisticians is also clearly 
evident in this study.12 This approach 
is increasingly being invoked in related 
fields and may become essential with a 
disease as heterogenous and ﬁckle as IgA 
nephropathy, to achieve robust and mean-
ingful analysis of smaller patient cohorts, 
a principle used in one recent study on 
prognostic indices with little more than 20 
patients,16 and in another with fewer than 
40 patients.3 Adoption of methodology 
with rigorous and contemporary math-
ematical frameworking in clinical studies 
of IgA nephropathy is likely to become the 
norm rather than the exception, thus accel-
erating research progress. The next decade 
of the 21st century is anticipated as an excit-
ing and productive time, with the prospect 
of rapid progress in our understanding of 
the pathogenesis and optimal treatments of 
IgA nephropathy.
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Calcium, cyclic AMP, and MAP 
kinases: Dysregulation in 
polycystic kidney disease
BD Cowley Jr.1
Low intracellular calcium, present in untreated polycystic kidney 
epithelia, results in a proliferative response to cyclic adenosine 
monophosphate. Treatment with a calcium channel blocker (CCB) 
caused exacerbation of autosomal dominant polycystic kidney disease 
in rats. Data regarding use of CCBs in human polycystic kidney disease 
(PKD) are limited and mixed. Thus, it is premature to extrapolate these 
findings to human PKD.
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Cyst development in polycystic kidney 
disease (PKD) requires epithelial-cell 
proliferation, ﬂuid secretion into closed 
cyst cavities, and extracellular matrix 
remodeling. Abnormal proliferation and 
ﬂuid secretion in PKD are at least partially 
mediated by intracellular cyclic adenosine 
monophosphate (cAMP). Autosomal 
dominant PKD (ADPKD) is associated 
with a phenotypic change in the epithelial 
cellular response to intracellular cAMP. 
In normal renal epithelial cells, cAMP 
is antiproliferative; however, in ADPKD 
epithelial cells, cAMP is pro-prolifera-
tive. This phenotypic change appears to be 
associated with decreases in intracellular 
calcium (Ca2+) with a resultant change in 
intracellular signaling through mitogen-
activated protein (MAP) kinase pathways 
(Figure 1). Speciﬁcally, in normal renal 
epithelia, increased intracellular cAMP 
results in inhibition of Raf-1/MAP kinase 
kinase/extracellular signal-regulated 
kinase (Raf-1/MEK/ERK) and is thus 
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antiproliferative. B-Raf, which can inde-
pendently stimulate MEK, is inhibited 
by Akt with normal intracellular Ca2+. 
In epithelia from polycystic kidneys, low 
intracellular Ca2+ abrogates Akt inhibition 
of B-Raf, and increased intracellular cAMP 
results in activation of B-Raf/MEK/ERK, 
which is pro-proliferative.1
Previous studies have shown that 
increased intracellular Ca2+ restores a 
normal proliferative phenotype in epi-
thelial cells from polycystic kidneys1 
and that a reduction in intracellular 
Ca2+ caused by Ca2+ channel block-
ers (CCBs) in normal human kidney 
cells led to cAMP-dependent cellular 
proliferation.2 Nagao et al.3 (this issue) 
further illuminate the role of intracell-
ular Ca2+ in the abnormal proliferation 
in PKD by examining the eﬀect of a non-
dihydropyridine CCB on PKD progres-
sion in the Han:SPRD rodent model of 
ADPKD. They present convincing data 
to support the concept that Ca2+ channel 
blockade accelerates the progression of 
PKD in the Han:SPRD rat, as manifested 
by increased kidney size and serum urea 
concentrations. This was associated with 
activation of the MEK/ERK pathway and 
an increase in cells positive for prolif-
erating-cell nuclear antigen. This study 
illustrates the translation of concepts 
regarding disease pathogenesis that 
were initially demonstrated in vitro to 
the actual disease state in vivo, albeit in 
one animal model.
The cellular pathophysiology that 
results in decreased intracellular Ca2+ in 
PKD is not deﬁnitively known; however, 
a role for disruption of Ca2+ homeosta-
sis due to defects in Ca2+ traﬃcking has 
been suggested. Polycystin 2 can act as 
a cation channel with high permeability 
for Ca2+. Polycystin 1 and polycystin 2 
have been shown to physically interact, 
and thus polycystin 1 may regulate cat-
ion traﬃc through polycystin 2. There-
fore, mutation in either polycystin 1 or 
polycystin 2 could cause disruption of 
Ca2+ homeostasis.4 Several types of Ca2+ 
channels have been described, including 
voltage-operated Ca2+ channels, which 
are blocked by traditional CCBs as used 
by Nagao et al.;3 receptor-operated Ca2+ 
channels; and store-operated Ca2+ chan-
nels.5 It is thought that many types of 
Ca2+ channels are present in the kidney, 
including many individual subclasses of 
each type.5–7 It is of note that polcys-
tin 2 is phylogenetically related to the 
transient receptor potential (TRP) fam-
ily of Ca2+ channels,7 which can act as 
store-operated Ca2+ channels.5,7 The fact 
that the mutation causing PKD in the 
Han:SPRD rat does not involve PKD1 
or PKD2 only serves to strengthen the 
argument that abnormalities of Ca2+ 
regulation are important in the patho-
genesis of PKD caused by a variety of 
genetic defects. If disruption of polycys-
tin 2 function, by mutation of polycystin 
1 or polycystin 2, results in impaired 
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Figure 1 | Proposed signal transduction pathways in normal human kidney (NHK) cells (a) 
and polycystic kidney disease (PKD) cells (b). AC, adenylate cyclase; ERK, extracellular signal-
regulated kinase; MEK, MAP kinase kinase; PC, polycystin; PI3K, phosphatidylinositol-3′-kinase; 
PKA, protein kinase A. (Adapted from ref. 1.)
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polycystin 2-mediated store-operated 
Ca2+ inﬂux, then the addition of a tra-
ditional CCB, which would block volt-
age-operated Ca2+ inﬂux, could result 
in even more profound decreases in 
intracellular Ca2+. It is unclear whether 
the change from a cAMP antiprolifera-
tive phenotype to a cAMP pro-prolif-
erative phenotype varies continuously 
with the decrease in intracellular Ca2+ 
or whether there is a threshold Ca2+ 
concentration below which a phenotypic 
switch occurs. In vitro studies using 
cystic epithelia from human ADPKD 
kidneys demonstrated proliferation in 
response to 8-Br-cAMP and the appear-
ance of increased proliferation with the 
combination of 8-Br-cAMP and a CCB, 
but the increase was not statistically sig-
niﬁcant.1 An in vivo study of CCB eﬀects 
in one of the innovative PKD1 or PKD2 
mutant animal models may be of interest 
in this regard.
In human ADPKD, hypertension is 
associated with an increased likelihood 
for progressive deterioration of renal 
function,8 and control of hypertension 
is protective. It has also been suggested 
that abrogation of the renin–angio-
tensin–aldosterone system (RAAS) in 
ADPKD with angiotensin-converting 
enzyme (ACE) inhibitors or angiotensin 
receptor blockers may be more beneﬁ-
cial than other agents in this regard,8–10 
though not all studies support this 
concept.11,12 In other chronic pro-
gressive renal diseases associated with 
proteinuria, combination therapy with 
an ACE inhibitor plus an angiotensin 
receptor blocker has been shown to pre-
serve renal function better than either 
agent alone.13 In a similar vein, interest 
in more eﬀective abrogation of the RAAS 
in PKD has led to the HALT PKD study, 
in which therapy with an ACE inhibitor 
alone is being compared with combina-
tion therapy with an ACE inhibitor plus 
an angiotensin receptor blocker.
Studies of treatments for PKD in ani-
mal models have occasionally shown 
disparate effects in different animal 
models.14 Thus, assessment of the eﬀect 
of CCBs in other animal models may be 
of some interest. In addition, assessment 
of the eﬀect of diﬀerent classes of CCBs 
may be of some interest. However, non-
dihydropyridine CCBs, such as vera-
pamil, which was used by Nagao et al.,3 
have been shown to be renoprotective 
in renal disease associated with diabe-
tes, whereas dihydropyridine CCBs are 
not.15 Thus, one would not be inclined 
to predict that dihydropyridine CCBs 
would be more beneficial than non-
dihydropyridine CCBs in PKD.
Hypertension is a risk factor for pro-
gression of all types of renal disease and 
increases the risk of other cardiovascular 
complications. Thus, control of hyper-
tension is of clear importance. There is 
no consensus in the existing literature, 
which is limited, regarding a detrimental 
eﬀect of CCBs in human ADPKD.8,10,11 
The ﬁndings of Nagao et al.3 may induce 
some hesitation regarding the use of 
CCBs to treat hypertension in PKD, 
and the use of other antihypertensives, 
including those that abrogate the RAAS, 
is certainly appropriate—many would 
say preferred. However, since CCBs are 
very eﬀective antihypertensive agents, 
their continued use in selected patients 
seems warranted until more deﬁnitive 
data suggest otherwise.
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